Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decitabine reverses innate immune gene suppression in rare melanomas.

Molecular cancer therapeutics·2026
Same author

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Trends and Outcomes of Surgical Reconstruction of the IVC after Oncologic Resection.

Journal of the American College of Surgeons·2026
Same author

The Impact of Hospital Mergers: Exploring the Importance of Flagship Designation, Hospital Volume, and Surgeon Volume on Perioperative Outcomes Following Whipple Procedure.

Journal of surgical oncology·2026
Same author

The Validity of Frailty Scoring in Preoperative Risk Assessment for Patients in the Surgical Intensive Care Unit.

The Journal of surgical research·2025

Related Experiment Video

Updated: May 27, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Debulking surgery in advanced melanoma.

Csaba Gajdos1, Martin D McCarter

  • 1Department of Surgery, University of Colorado at Denver, Mail Stop C313, 12631 East 17th Avenue, Aurora, CO 80045, USA. csaba.gajdos@ucdenver.edu

Expert Review of Anticancer Therapy
|November 5, 2011
PubMed
Summary

Surgical debulking may benefit select stage IV melanoma patients, especially with isolated disease. Advances in systemic therapies are influencing the role of this surgery, impacting patient selection and quality of life.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 27, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Area of Science:

  • Oncology
  • Surgical Oncology
  • Melanoma Research

Background:

  • Stage IV melanoma generally presents with poor prognosis.
  • Certain patients with stage IV melanoma are candidates for surgical debulking.
  • Retrospective data suggest improved patient selection for surgical resection in isolated stage IV disease.
  • Palliative resections can enhance quality of life in carefully selected individuals.

Purpose of the Study:

  • To discuss the impact of novel systemic therapies on the clinical utility of debulking surgery for melanoma.
  • To review the existing literature concerning the rationale, risks, benefits, and patient selection criteria for debulking surgery in melanoma.

Main Methods:

  • Review of current literature on melanoma systemic therapies.
  • Analysis of retrospective evidence on surgical debulking in stage IV melanoma.
  • Evaluation of patient selection criteria for palliative and potentially curative resections.

Main Results:

  • Growing evidence supports patient selection for surgical resection in isolated stage IV melanoma.
  • Palliative resections may improve quality of life in specific patient groups.
  • Emerging systemic therapies may alter the landscape for surgical debulking.

Conclusions:

  • Surgical debulking remains a consideration for select stage IV melanoma patients.
  • The integration of new systemic treatments necessitates a re-evaluation of surgical approaches.
  • Careful patient selection is paramount for optimizing outcomes and quality of life.